

# ANKYLOSING SPONDYLITIS REFERRAL FORM (A-R)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION					
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN	Primary Language
Address		City	State		ZIP
Email		Home Phone	Work Phone		Cell Phone
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT					
Primary Caregiver/Alt Contact Name (If applicable)			Alt Contact Email		Alt Contact Phone

PRESCRIBER INFORMATION					
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax		
Referral Contact Email		Office Phone	Office Fax		
Practice / Facility Name		Prescriber Name / Specialty			
Address		City	State	ZIP	
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #		

**\* Please include a copy of the front and back of insurance card \***

CLINICAL INFORMATION - Please include applicable clinical chart notes					
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>					Therapy Start Date
Date of Diagnosis	Years with Disease		Prior Therapy <input type="checkbox"/> No <input type="checkbox"/> Yes (please list)		
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:	
If self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Other/Concomitant Medications (please list)					
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)			<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)					
ICD-10 Code <input type="checkbox"/> M45.0 Ankylosing spondylitis of multiple sites in spine <input type="checkbox"/> M45.1 Ankylosing spondylitis of occipito-atlanto-axial region <input type="checkbox"/> M45.2 Ankylosing spondylitis of cervical region <input type="checkbox"/> M45.3 Ankylosing spondylitis of cervicothoracic region <input type="checkbox"/> M45.4 Ankylosing spondylitis of thoracic region <input type="checkbox"/> M45.5 Ankylosing spondylitis of thoracolumbar region <input type="checkbox"/> M45.6 Ankylosing spondylitis of lumbar region <input type="checkbox"/> M45.7 Ankylosing spondylitis of lumbosacral region <input type="checkbox"/> M45.8 Ankylosing spondylitis sacral and sacrococcygeal region <input type="checkbox"/> M45.9 Ankylosing spondylitis of unspecified sites in spine					

**PRESCRIPTION INFORMATION - Please Escribe if required by state law**  
*In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.*

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> Starter Kit <input type="checkbox"/> 200mg Prefilled Syringe <input type="checkbox"/> 200mg Lyophilized Vial	Starter Dose: <input type="checkbox"/> Inject 400mg SubQ once at weeks 0, 2 and 4  Maintenance Dose: <input type="checkbox"/> Inject 200mg SubQ once every 2 weeks <input type="checkbox"/> Inject 400mg SubQ once every 4 weeks	6  4-week supply	0
<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> 150mg/mL Prefilled Syringe <input type="checkbox"/> 150mg/mL Pen <input type="checkbox"/> 150 mg/mL Sensoready Pen	Loading Dose: <input type="checkbox"/> Inject 150mg SubQ once at weeks 0, 1, 2, 3 and 4  Maintenance Dose: <input type="checkbox"/> Inject 150 mg SubQ once every 4 weeks <input type="checkbox"/> Inject 300 mg (2x150 mg injections) SubQ once every 4 weeks	10  28 days	
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 25mg/0.5mL Prefilled Syringe <input type="checkbox"/> 25mg/0.5mL Single Dose Vial <input type="checkbox"/> 50mg/mL Sureclick Autoinjector <input type="checkbox"/> 50mg/mL Prefilled Syringe <input type="checkbox"/> Mini 50mg/mL Cartridge	<input type="checkbox"/> Inject 50mg SubQ once weekly <input type="checkbox"/> Inject 25mg SubQ twice weekly	4-week supply	
<input type="checkbox"/> Humira CF (adalimumab)	<input type="checkbox"/> 40mg/0.4mL Prefilled Syringe <input type="checkbox"/> 40mg/0.4mL Pen	<input type="checkbox"/> Inject 40mg SubQ every other week	4-week supply	
<input type="checkbox"/> Remicade (infliximab)	<input type="checkbox"/> 100mg vial	Loading Dose: <input type="checkbox"/> Infuse 5mg/kg IV at weeks 0, 2, and 6  Maintenance Dose: <input type="checkbox"/> Infuse 5mg/kg IV every six weeks	QS  6 weeks	0

_____ Prescriber Signature	_____ Date	_____ Supervising Physician Signature (where required by state law)	_____ Date
_____ DAW (Dispense as Written)	_____ Date	_____ Brand Necessary (must handwrite)	

**Note:** The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

**Confidentiality Statement:** This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

# ANKYLOSING SPONDYLITIS REFERRAL FORM (S-Z)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

## PATIENT INFORMATION

Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN	Primary Language
Address		City	State		ZIP
Email	Home Phone	Work Phone		Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT					
Primary Caregiver/Alt Contact Name (If applicable)			Alt Contact Email		Alt Contact Phone

## PRESCRIBER INFORMATION

Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax		
Referral Contact Email		Office Phone	Office Fax		
Practice / Facility Name		Prescriber Name / Specialty			
Address		City	State	ZIP	
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #		

*\* Please include a copy of the front and back of insurance card \**

## CLINICAL INFORMATION - Please include applicable clinical chart notes

Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>				Therapy Start Date	
Date of Diagnosis	Years with Disease	Prior Therapy <input type="checkbox"/> No <input type="checkbox"/> Yes (please list)			
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:	
If self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Other/Concomitant Medications (please list)					
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)			<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)					
ICD-10 Code <input type="checkbox"/> M45.0 Ankylosing spondylitis of multiple sites in spine <input type="checkbox"/> M45.1 Ankylosing spondylitis of occipito-atlanto-axial region <input type="checkbox"/> M45.2 Ankylosing spondylitis of cervical region <input type="checkbox"/> M45.3 Ankylosing spondylitis of cervicothoracic region <input type="checkbox"/> M45.4 Ankylosing spondylitis of thoracic region <input type="checkbox"/> M45.5 Ankylosing spondylitis of thoracolumbar region <input type="checkbox"/> M45.6 Ankylosing spondylitis of lumbar region <input type="checkbox"/> M45.7 Ankylosing spondylitis of lumbosacral region <input type="checkbox"/> M45.8 Ankylosing spondylitis sacral and sacrococcygeal region <input type="checkbox"/> M45.9 Ankylosing spondylitis of unspecified sites in spine					

## PRESCRIPTION INFORMATION - Please Escribe if required by state law

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50mg/0.5mL Prefilled Syringe <input type="checkbox"/> 50mg/0.5mL Smartject Pen	No Loading Dose Required: <input type="checkbox"/> Inject 50mg SubQ once a month	1 month supply	
<input type="checkbox"/> Simponi Aria (golimumab)	<input type="checkbox"/> 50mg/4mL Vial	Loading Dose: <input type="checkbox"/> Infuse 2 mg/kg IV at weeks 0 and 4  Maintenance Dose: <input type="checkbox"/> Infuse 2 mg/kg IV every 8 weeks	QS  8 weeks	0
<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> 80mg/mL Prefilled Syringe <input type="checkbox"/> 80mg/mL Autoinjector	Loading Dose: <input type="checkbox"/> Inject 160 mg (2x80 mg injections) SubQ once on Day 1  Maintenance Dose: <input type="checkbox"/> Inject 80mg SubQ once every 4 weeks	2  4-week supply	0
<input type="checkbox"/> Xeljanz	<input type="checkbox"/> 5mg tablet	<input type="checkbox"/> Take one tablet by mouth twice daily	60	
<input type="checkbox"/> Xeljanz XR	<input type="checkbox"/> 11mg tablet	<input type="checkbox"/> Take one tablet by mouth once daily	30	

Prescriber Signature

Date

Supervising Physician Signature (where required by state law)

Date

DAW (Dispense as Written)

Date

Brand Necessary (must handwrite)

**Note:** The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

**Confidentiality Statement:** This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.